EXACT SCIENCES CORP Form 10-Q May 15, 2009 Table of Contents

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2009

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission File Number: 000-32179

EXACT SCIENCES CORPORATION

(Exact name of registrant as specified in its charter)

DELAWARE 02-0478229

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

100 Campus Drive, Marlborough, Massachusetts

(Address of principal executive offices)

01752 (Zip Code)

(508) 683-1200

(Registrant s telephone number, including area code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes x No o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes £ No £

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer o

Accelerated filer o

Non-accelerated filer o (Do not check if a smaller reporting company)

Smaller reporting company x

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes o No x

As of May 15, 2009, the registrant had 30,887,484 shares of Common Stock outstanding.

Table of Contents

EXACT SCIENCES CORPORATION

INDEX

		Page Number
	Part I - Financial Information	
Item 1.	Financial Statements	
	Condensed Consolidated Balance Sheets (Unaudited) as of March 31, 2009 and December 31, 2008	3
	Condensed Consolidated Statements of Operations (Unaudited) for the Three Months Ended March 31, 2009 and 2008	4
	Condensed Consolidated Statements of Cash Flows (Unaudited) for the Three Months Ended March 31, 2009 and 2008	5
	Notes to Condensed Consolidated Financial Statements (Unaudited)	ϵ
Item 2.	Management s Discussion and Analysis of Financial Condition and Results of Operations	20
Item 3.	Quantitative and Qualitative Disclosures about Market Risk	26
Item 4T.	Controls and Procedures	26
	Part II - Other Information	
Item 1A.	Risk Factors	27
Item 6.	<u>Exhibits</u>	28
	<u>Signatures</u>	29
	Exhibit Index	30
	2	

Table of Contents

EXACT SCIENCES CORPORATION

Condensed Consolidated Balance Sheets

(Amounts in thousands, except share data - unaudited)

	March 31, 2009	December 31, 2008
ASSETS		
Current Assets:		
Cash and cash equivalents	\$ 3,595	\$ 4,937
Marketable securities	17,018	
Prepaid expenses and other current assets	690	190
Total current assets	21,303	5,127
Property and Equipment, at cost:		
Laboratory equipment	174	174
Office and computer equipment	22	13
Leasehold improvements		
Furniture and fixtures		
	196	187
Less Accumulated depreciation and amortization	(123)	(111)
·	73	76
Patent costs, net of accumulated amortization of \$2,820 at December 31, 2008		95
Restricted cash	600	600
	\$ 21,976	\$ 5,898
LIABILITIES AND STOCKHOLDERS DEFICIT	· ·	
Current Liabilities:		
Accounts payable	\$ 34	\$ 683
Accrued expenses	1,234	1,498
Third party royalty obligation, current portion	1,000	1,500
Deferred license fees, current portion	4,986	1,350
Total current liabilities	7,254	5,031
Third party royalty obligation, less current portion	965	1,950
Deferred license fees, less current portion	14,901	1,350
•		
Commitments and contingencies		
Stockholders Deficit:		
Preferred stock, \$0.01 par value Authorized 5,000,000 shares Issued and outstanding 0 shares		
at March 31, 2009 and December 31, 2008, respectively		
Common stock, \$0.01 par value Authorized 100,000,000 shares Issued and		
outstanding 30,848,070 and 27,522,931 shares at March 31, 2009 and December 31, 2008,		
respectively	308	275
Additional paid-in capital	174,878	169,854
Treasury stock, at cost, 85,550 shares	(97)	(97)
Other comprehensive income	71	
Accumulated deficit	(176,304)	(172,465)
Total stockholders deficit	(1,144)	(2,433)
	\$ 21,976	\$ 5,898

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

EXACT SCIENCES CORPORATION

Condensed Consolidated Statements of Operations

(Amounts in thousands, except per share data - unaudited)

		Three Months Ended March 31,			
	2	009		2008	
Revenue:					
Product royalty fees	\$	7	\$	(292)	
License fees		993		338	
Product				5	
		1,000		51	
Cost of revenue:					
Product royalty fees				1	
Gross profit		1,000		50	